Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms on their most important mergers, acquisitions and takeover transactions.
Alexion Pharmaceuticals Completes Acquisition of Portola Pharmaceuticals
- Client News
- July 2, 2020
Paul, Weiss advised Alexion Pharmaceuticals, Inc. in its acquisition of Portola Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Under the terms of the transaction, Alexion acquired all of Portola’s outstanding shares of common stock at $18.00 per share in cash, without interest.
The Paul, Weiss team included, among others, corporate partners Scott Barshay, John Kennedy and Raphael Russo, and counsel Patricia Vaz de Almeida; intellectual property partner Jonathan Ashtor; employee benefits partner Jean McLoughlin and counsel Reuven Falik and Jarrett Hoffman; litigation partner Jaren Janghorbani and counsel Rachel Fiorill; tax partner Robert Holo; real estate partner Peter Fisch; and antitrust counsel Yuni Sobel and Marta Kelly.